ChromaDex announces results of second human clinical study of NIAGEN
ChromaDex announced that the initial results of its second human clinical study of NIAGEN nicotinamide riboside chloride, or NR, have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide, or NAD+, in 140 healthy human volunteers over 8-weeks. In this study, participants in the active group received 100, 300, or 1000mg per day. Results from the randomized, double-blind, placebo controlled, parallel-arm trial demonstrated that NR produced statistically significant increases in blood NAD+ compared to placebo that were related to the dose of NR consumed, demonstrating a dose response. Levels remained elevated throughout the duration of the study, thereby establishing an efficacious range for daily consumption. The study confirms not only efficacy in raising NAD+, but also definitively documents the safety of daily use of NR. The full results of the study will be submitted for publication in a peer review journal shortly.